Document Detail

Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.
MedLine Citation:
PMID:  23135775     Owner:  NLM     Status:  Publisher    
New molecularly targeted therapies are needed for childhood ependymoma. Angiogenesis and the PDGFR pathway could be potential therapeutic targets. This study aimed to screen ependymomas for the expression and clinicopathological correlates of angiogenic factors and potential therapeutic targets including VEGFR, endoglin (CD105), CD34, CD31, c-Kit, PDGFR-α and PDGFR-β. Immunohistochemistry for angiogenesis factors and PDGFR-α and β was performed in 24 archival tumor samples from children and adults treated for ependymoma at our institution. CD31 density, CD105 density and pericyte coverage index (PCI) were calculated. These findings were correlated with clinical outcome. VEGFR2 was overexpressed in tumor cells in only one out of 24 cases, but was found overexpressed in the vessels in 6 cases. PDGFR-α and β were found to be over-expressed in the ependymoma tumor cells in seven out of 24 cases (29.2 %). CD31 density, CD105 density and PCI did not correlate with expression of PDGFRs. Overexpression of PDGFR-α and β in tumor cells and overexpression of PDGFR-α in tumor endothelium had prognostic significance and this was maintained in multivariate analysis for overexpression of PDGFR-α in tumor cells (2 year progression free survival was 16.7 ± 15.2 for cases with overexpression of PDGFR-α in the tumor vs. 74.5 ± 15.2 for those with low/no expression, hazard ratio = 5.78, p = 0.04). A number of angiogenic factors are expressed in ependymoma tumor cells and tumor endothelium. Preliminary evidence suggests that the expression of PDGFRs could have a prognostic significance in ependymoma. This data suggests that PDGFRs should be further evaluated as targets using novel PDGFR inhibitors.
Lucas Moreno; Sergey Popov; Alexa Jury; Saffa Al Sarraj; Chris Jones; Stergios Zacharoulis
Related Documents :
17721995 - Role of high-molecular weight tropomyosins in tgf-beta-mediated control of cell motility.
23449405 - Development of incurable cancer cell targeted agents using viral technology.
15352035 - Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacologi...
17981715 - New cancer therapy using genetically-engineered oncolytic sendai virus vector.
14654905 - Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with v...
16783835 - Polyamine depletion by odc-adometdc antisense adenovirus impairs human colorectal cance...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  -     ISSN:  1573-7373     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tramadol and levobupivacaine wound infiltration at Cesarean delivery for postoperative analgesia.
Next Document:  (1)H, (13)C, (15)N resonance assignments of murine hepatitis virus nonstructural protein 3a.